Joining the 2023 ACR/CHEST guideline for the treatment of ILD in people with SARDs is a 2024 guideline from the American Thoracic Society (ATS) focused on treatment of SSc-ILD. “You now have in ...
Two posters will highlight new data from the company’s open-label ASCENT study of LIQ861 (YUTREPIA) in PH-ILD patients with a focus on safety, tolerability, exploratory changes in 6-minute walk ...
Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in six-minute walk ...
Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety ... three posters at the American Thoracic Society (ATS) 2025 International Conference, taking place ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback